Mahamaya Lifesciences Share Price & Earnings Call Analysis
- Market cap
- ₹423 Cr
- P/E
- 25.61
- ROE
- 19.29%
- PEG
- 0.40
- Price to sales
- 1.29
- Debt to equity
- 0.74
- 52W high / low
- ₹201 / ₹114
- EBITDA margin
- 10.19%
- Net profit margin
- 5.02%
- Promoter holding
- 56.39%
- Sales (last year)
- ₹329 Cr
ncorporated in 2002, Mahamaya Lifesciences Limited is engaged in manufacturing, registration and export of finest crop protection products and bioproducts for crop & soil health management.[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Fertilizers & Agrochemicals
on management's own guidance
- Dharmaj CropGood growth2
- Anya Polytech &Good growth1
- M B Agro Prod.Good growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Fertilizers & Agrochemicals companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | Anya Polytech & | 20–40% | Up 2%+ | ₹194 Cr | 23.2 |
| 2 | Dharmaj Crop | 20–40% | Up 0–2% | ₹862 Cr | 14.3 |
| 3 | M B Agro Prod. | 20–40% | Flat | ₹8,127 Cr | 52.5 |
| 4 | 20–40% | Flat | ₹7,066 Cr | 35.9 | |
| 5 | 10–20% | Up 2%+ | ₹1,167 Cr | 17.4 | |
| 6 | 10–20% | Flat | ₹50,035 Cr | 26.8 |
Sign up free to see every company in the sector ranking and track Mahamaya Lifesciences.
Pro shows every company guiding 40%+ revenue growth →Full Fertilizers & Agrochemicals rankingFinancials of Mahamaya Lifesciences
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Mahamaya Lifesciences
Quarterly Results
Quarter-by-quarter operating performance
Financials of Mahamaya Lifesciences
Profit & Loss
Annual income statement trend
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Sales + | 90 | 137 | 161 | 264 | 329 |
| Expenses + | 84 | 128 | 148 | 241 | 296 |
| Operating Profit | 6 | 9 | 13 | 23 | 34 |
| OPM % | 7% | 6% | 8% | 9% | 10% |
| Other Income + | 0 | 0 | 1 | 3 | 1 |
| Interest | 2 | 3 | 6 | 7 | 8 |
| Depreciation | 1 | 1 | 1 | 2 | 2 |
| Profit before tax | 4 | 5 | 7 | 17 | 24 |
| Tax % | 27% | 26% | 27% | 25% | 31% |
| Net Profit + | 3 | 4 | 5 | 13 | 17 |
| EPS in Rs | 21.78 | 30.03 | 41.80 | 7.28 | 7.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
Financials of Mahamaya Lifesciences
Balance Sheet
Capital structure and asset base
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 18 | 23 |
| Reserves | 14 | 18 | 23 | 32 | 99 |
| Borrowings + | 19 | 24 | 55 | 58 | 91 |
| Other Liabilities + | 21 | 34 | 33 | 81 | 98 |
| Total Liabilities | 56 | 78 | 112 | 188 | 310 |
| Fixed Assets + | 20 | 21 | 21 | 27 | 38 |
| CWIP | 2 | 2 | 3 | 4 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 34 | 54 | 88 | 157 | 267 |
| Total Assets | 56 | 78 | 112 | 188 | 310 |
Financials of Mahamaya Lifesciences
Cash Flows
Operating, investing and financing cash movement
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Cash from Operating Activity + | 2 | 1 | -23 | 1 | -30 |
| Cash from Investing Activity + | -3 | -3 | -2 | -8 | -16 |
| Cash from Financing Activity + | 1 | 2 | 24 | 9 | 81 |
| Net Cash Flow | 0 | 1 | -0 | 1 | 35 |
| Free Cash Flow | -1 | -2 | -25 | -8 | -46 |
| CFO/OP | 56% | 24% | -163% | 12% | -75% |
Financials of Mahamaya Lifesciences
Ratios
Working capital efficiency and return ratios
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 37 | 25 | 64 | 67 | 78 |
| Inventory Days | 93 | 109 | 137 | 167 | |
| Days Payable | 83 | 87 | 61 | 92 | |
| Cash Conversion Cycle | 47 | 48 | 140 | 142 | 78 |
| Working Capital Days | 8 | 9 | 14 | 29 | 49 |
| ROCE % | 20% | 21% | 26% | 20% |
Continue your research
Others in Fertilizers & Agrochemicals this season
- Chambal Fertilisers & Chemicals (Q2 FY27)
Q2-FY27 Operational Income (Standalone & Consolidated): INR 69,995 Mn, up 9% YoY vs Q2-FY26 (INR 64,128 Mn). Key investor presentation takeaways from Chambal Fe
- G S F C (Q2 FY27)
4,711 Crores, a 50% YoY growth (Page 2) . Key investor presentation takeaways from Gujarat State Fertilizers & Chemicals Ltd's Q2 FY27 investor presentation — a
- Zuari Agro Chemicals (Q2 FY27)
398.54 crores for the quarter ended 30th September 2026 and Rs. Key results statement takeaways from Zuari Agro Chemicals Ltd's Q2 FY27 results statement — and
- UPL (Q2 FY27)
UPL Limited Q2FY27 Revenue:** ₹11,860 crore, down 1% YoY (Q2FY26: ₹12,019 crore) . Key investor presentation takeaways from UPL Ltd's Q2 FY27 investor presentat